两对三输液方案的N-乙半氨酸为乙氨基过量
Shadi Tamur1, Bader Alyahya2, Faisal Alsani3
1Department of Pediatrics, College of Medicine, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Pediatric reports
|March 27, 2024
概括
简化两次输注N-乙半氨酸 (NAC) 治疗乙氨基过量治疗方案与标准的三次输注方法一样有效. 这种替代方案减少了施用错误,提高了儿童患者治疗的安全性和简单性.
科学领域:
- 儿科毒理学 儿科毒理学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 乙氨基过量服用是药物诱导的肝损伤的常见原因.
- 目前FDA批准的N-乙半氨酸 (NAC) 治疗涉及一个复杂的,三次输液协议.
- 简化两次输注NAC方案可能在给药和患者安全方面提供优势.
研究的目的:
- 为了比较两个输注NAC方案的疗效和安全性与标准的三输注方案在儿科患者急性乙氨基过量.
- 评估两种NAC治疗方案之间的肝毒性率,注射错误和不良反应的差异.
主要方法:
- 蒙特利尔儿童医院的回顾性研究比较了2003年之前的三输注NAC治疗与两输注治疗方案.
- 收集的数据包括患者人口统计,NAC的管理细节,错误,肝毒性率和不良反应.
- 用于数据的统计分析,使用了奇平方测试.
主要成果:
- 两次输液组 (65名患者) 与三次输液组 (61名患者,23个错误;p < 0.001) 相比,输液组 (4) 的注射错误显著减少.
- 肝毒性率在两组之间是相似的,在两种疗法中都没有报告肝移植或死亡病例.
- 副作用在两组中发生的频率相同,并且通过调整输液速率可以控制.
结论:
- 两次输注NAC疗法在预防肝损伤和改善儿科乙氨基过量治疗的结果方面,表现出与三次输注疗法相似的疗效.
- 双输注方案在减少注射错误方面提供了显著的优势,这表明了更好的安全性和简单性.
- 建议对更大的队列进行进一步研究,以验证这些发现并优化NAC治疗策略.
相关概念视频
Prevention of Further Absorption of Poison
820
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
820
Anticholinesterase Agents: Poisoning and Treatment
851
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
851
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
199
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
199
Enhanced Elimination of Poison
505
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
505
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162


